IXICO board members

Charles Spicer

Non-executive chairman

Charles is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He is Non-Executive Chairman of Realm Therapeutics plc, Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health Invention for Innovation Funding Panel.
Appointment to Board:
October 2013

Giulio Cerroni

Chief Executive Officer

Giulio has over thirty years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at Thermo Fisher Scientific, Inc. and LGC Ltd, where he transformed the scale of LGC’s Genomics division, completing 3 acquisitions in under eighteen months. Giulio was a member of the executive leadership team responsible for the successful sale of LGC Ltd to global investment firm, KKR & Co. Inc.
Appointment to Board:
February 2017

Tim Sharpington

Non-Executive Director and Senior Independent Director

Tim has more than twenty-five years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. Tim is currently Chief Operating Officer at hVIVO plc. He has broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. His previous positions include Chief Executive Officer at Phytopharm plc and Serentis Limited and Executive Vice President at Vectura plc. Tim chairs the Remuneration Committee and is a member of the Audit Committee.
Appointment to Board:
October 2013

Mark Warne

Non-Executive Director

Mark is Chief Executive Officer of DeepMatter Group plc. Mark is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. Mark is a Non-Executive Director of hVIVO plc. Mark is a member of the Audit and Remuneration Committees.
Appointment to Board:
September 2016

John Bradshaw

Non-Executive Director

John is a chartered accountant with more than twenty years’ experience as a Chief Financial Officer with venture-capital-backed and listed companies. He is the Chief Financial Officer of Syncona Investment Management Limited, the Investment Manager of Syncona Limited. He is a Non-Executive Director and Audit Committee Chair of Creo Medical Group plc. John chairs the Audit Committee and is a member of the Remuneration Committee.
Appointment to Board:
October 2013

Grant Nash

EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

Grant has worked in the life sciences sector for over 15 years. In his executive director role, Grant leads the Company's Finance, Legal and IT functions. Grant joined IXICO from UK Biobank, an international health research data resource, where he had been Finance Director since 2014. Previous to this he was SVP Finance at Evotec, the early stage drug discovery CRO.

Appointment to Board:
August 2019